On July 28, Uganda’s Ministry of Health declared the country free of its Ebola outbreak, 42 days after the last confirmed locally transmitted case tested negative and was discharged from care. The announcement, reported in The Lancet, came with a warning: the same virus, Bundibugyo ebolavirus, continues to spread across the border in the Democratic Republic of the Congo, and the risk of imported cases has not gone away.
Uganda’s outbreak was part of a regional epidemic that began in May 2026, when the Bundibugyo species of Ebola was confirmed in both the DRC and Uganda. The species has no licensed vaccine and no specific treatment, a fact that shaped the response and made the end of the outbreak in one country a partial victory at best. The 42-day countdown, equivalent to two maximum incubation periods for Bundibugyo virus disease, began on July 16, when the last confirmed case was discharged after a second negative test. No new locally transmitted cases appeared in the following six weeks.
Across the border, the epidemic continues. As of early August, the DRC had reported nearly 4,000 confirmed cases of Bundibugyo virus disease, with more than 1,800 deaths. Ituri province remains the epicenter, with the vast majority of cases and deaths concentrated in a remote, densely populated region already strained by insecurity and humanitarian crisis. The outbreak has also spilled beyond the region: in May, an infected US citizen was medically evacuated to Germany; in June, a French humanitarian doctor returning from the DRC tested positive; in July, a US citizen working for a humanitarian organization in the DRC was confirmed infected.
The Lancet report, a World Report by journalist Paul Adepoju, places Uganda’s declaration in this regional context. Uganda brought transmission under control through surveillance, contact tracing, and community engagement, coordinated with the World Health Organization and Africa CDC, but the porous border with the DRC means the work is not done. Cross-border preparedness, screening, and the maintenance of laboratory and treatment capacity remain essential as long as the virus circulates in the region.
For scientists, the outbreak has been a rare and difficult opportunity. Bundibugyo virus disease has been far less studied than the Zaire ebolavirus species responsible for the major West Africa and DRC outbreaks, and this epidemic has driven a push for the first clinical trial of treatments for the disease. A platform trial began enrolling patients in early July to test candidate therapies, and WHO’s technical advisory group has been working to prioritize vaccine candidates, though none is yet licensed. The end of the outbreak in Uganda does not end those efforts; the DRC epidemic provides both the need and the setting for them.
The declaration also shows how outbreaks end, and how they do not. An outbreak is declared over when the transmission chain is broken, not when the pathogen is gone, and the 42-day clock is a tool for confirming the former while remaining honest about the latter. Uganda’s achievement is real, and it was earned through sustained surveillance and community trust. But the region’s collective vulnerability remains, and the warning in the Lancet report is that the virus does not respect the border that Uganda’s declaration implicitly celebrates.
For neighboring countries and the international community, the practical implications are immediate. Surveillance at the Uganda-DRC border needs to remain at heightened levels, cross-border community networks built during the response should be maintained rather than dismantled, and the laboratory capacity that made rapid diagnosis possible cannot be allowed to atrophy between outbreaks. The WHO and Africa CDC have emphasized that regional health security depends on this kind of sustained investment, and the current outbreak has already shown how quickly a single undetected case can cross a border: the imported cases in Germany, France, and the United States all originated from travel out of the affected region.
Bundibugyo virus disease has historically been neglected relative to other Ebola species, precisely because outbreaks have been smaller and rarer. This epidemic changed that, and the research infrastructure built during the response, including the first treatment trial for the disease, offers a rare chance to close the knowledge gap. The DRC epidemic continues to provide the clinical need, and the trial’s results, when they come, will matter for every country in the region and beyond. Uganda’s declaration is both an ending for one transmission chain and the beginning of a more serious scientific engagement with a virus that has now shown, twice in a decade, that it can move across borders and demand attention.
Sources: Adepoju, P. Uganda ends Ebola outbreak but risk remains. The Lancet 408, 504 (2026). DOI: 10.1016/S0140-6736(26)01594-1. WHO Regional Office for Africa; ECDC outbreak situation reports; Al Jazeera, July 28, 2026.